Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

New research being presented at the European Congress on Obesity (ECO 2025) has found that patients of an online obesity ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...